Syndax Pharmaceuticals Inc. Insider Trading

SNDX

Last 12 months

Insiders sold $2.86M and bought nothing on the open market.

73% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in May 2025.

Net open-market

−$2.86M

0 buys · 9 sales

Under a 10b5-1 plan

73%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

May 2025

May 19, 2025

Get an email when SNDX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 29	Dennis Podlesak Director	Sold10b5-1 plan	8,000	$14.21	114K	3.2%	Form 4
Jul 8	Michael A Metzger Chief Executive Officer	Sold10b5-1 plan	32,375	$24.24	785K	6.3%	Form 4
Jun 11 – 12	Nicholas A.j. Botwood Head of R&D, CMO	Sold10b5-1 plan 2 parts	65,515	$18.07 average	$1.18M	52%	Form 4
Jun 1	Keith A. Goldan Chief Financial Officer	SoldNo plan	1,177	$18.99	22K	0.8%	Form 4
Jun 1	Michael A Metzger Chief Executive Officer	SoldNo plan	6,847	$18.99	130K	1.4%	Form 4
Feb 9	Michael A Metzger Chief Executive Officer	SoldNo plan	17,159	$21.03	361K	3.4%	Form 4
Feb 9	Keith A. Goldan Chief Financial Officer	SoldNo plan	3,410	$21.03	72K	2.4%	Form 4
Feb 6	Michael A Metzger Chief Executive Officer	SoldNo plan	7,412	$20.62	153K	1.4%	Form 4
Feb 6	Keith A. Goldan Chief Financial Officer	SoldNo plan	2,082	$20.62	43K	1.4%	Form 4
Sep 8, 2025	Michael A Metzger Chief Executive Officer	Sold10b5-1 plan	157,307	$16.41	$2.58M	34%	Form 4
Aug 14, 2025 – Aug 18, 2025	Dennis Podlesak Director	Sold10b5-1 plan 3 parts	57,600	$15.19 average	875K	23%	Form 4
Jul 16, 2025	Keith A. Goldan Chief Financial Officer	SoldNo plan	1,296	$9.29	12K	1.4%	Form 4
Jul 16, 2025	Michael A Metzger Chief Executive Officer	SoldNo plan	7,534	$9.29	70K	2.5%	Form 4
May 19, 2025	Keith A. Goldan Chief Financial Officer	Bought	3,000	—	—	3.3%	Form 4
May 19, 2025	Martin H. Huber Jr. Director	Bought	5,000	$8.99	45K	6.8%	Form 4
May 19, 2025	Keith Katkin Director	Bought	10,000	$9.11	91K	11%	Form 4
May 16, 2025	Nicholas A.j. Botwood Head of R&D, CMO	Bought	11,765	$9.00	106K	50%	Form 4
Mar 4, 2025	Michael A Metzger Chief Executive Officer	Sold10b5-1 plan	7,814	$15.05	118K	2.5%	Form 4
Feb 10, 2025	Keith A. Goldan Chief Financial Officer	SoldNo plan	3,777	$15.50	59K	4.0%	Form 4
Feb 10, 2025	Michael A Metzger Chief Executive Officer	SoldNo plan	13,288	$15.50	206K	4.2%	Form 4
Feb 10, 2025	Neil Gallagher President, Head of R&D	SoldNo plan	4,618	$15.50	72K	5.1%	Form 4

Oct 2910b5-1 plan
Dennis Podlesak
Director · sold 8,000 at $14.21
114K
3.2% of stake
Jul 810b5-1 plan
Michael A Metzger
Chief Executive Officer · sold 32,375 at $24.24
785K
6.3% of stake
Jun 11 – 1210b5-1 plan
Nicholas A.j. Botwood
Head of R&D, CMO · sold 65,515 at avg $18.07
$1.18M
52% of stake
Jun 1No plan
Keith A. Goldan
Chief Financial Officer · sold 1,177 at $18.99
22K
0.8% of stake
Jun 1No plan
Michael A Metzger
Chief Executive Officer · sold 6,847 at $18.99
130K
1.4% of stake
Feb 9No plan
Michael A Metzger
Chief Executive Officer · sold 17,159 at $21.03
361K
3.4% of stake
Feb 9No plan
Keith A. Goldan
Chief Financial Officer · sold 3,410 at $21.03
72K
2.4% of stake
Feb 6No plan
Michael A Metzger
Chief Executive Officer · sold 7,412 at $20.62
153K
1.4% of stake
Feb 6No plan
Keith A. Goldan
Chief Financial Officer · sold 2,082 at $20.62
43K
1.4% of stake
Sep 8, 202510b5-1 plan
Michael A Metzger
Chief Executive Officer · sold 157,307 at $16.41
$2.58M
34% of stake
Aug 14, 2025 – Aug 18, 202510b5-1 plan
Dennis Podlesak
Director · sold 57,600 at avg $15.19
875K
23% of stake
Jul 16, 2025No plan
Keith A. Goldan
Chief Financial Officer · sold 1,296 at $9.29
12K
1.4% of stake
Jul 16, 2025No plan
Michael A Metzger
Chief Executive Officer · sold 7,534 at $9.29
70K
2.5% of stake
May 19, 2025
Keith A. Goldan
Chief Financial Officer · bought 3,000
—
3.3% of stake
May 19, 2025
Martin H. Huber Jr.
Director · bought 5,000 at $8.99
45K
6.8% of stake
May 19, 2025
Keith Katkin
Director · bought 10,000 at $9.11
91K
11% of stake
May 16, 2025
Nicholas A.j. Botwood
Head of R&D, CMO · bought 11,765 at $9.00
106K
50% of stake
Mar 4, 202510b5-1 plan
Michael A Metzger
Chief Executive Officer · sold 7,814 at $15.05
118K
2.5% of stake
Feb 10, 2025No plan
Keith A. Goldan
Chief Financial Officer · sold 3,777 at $15.50
59K
4.0% of stake
Feb 10, 2025No plan
Michael A Metzger
Chief Executive Officer · sold 13,288 at $15.50
206K
4.2% of stake
Feb 10, 2025No plan
Neil Gallagher
President, Head of R&D · sold 4,618 at $15.50
72K
5.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SNDX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SNDX

CompareIntrinsic value

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

HROWHarrow Inc.

$28.75+0.74%46

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

EOLSEvolus Inc.

$7.47+1.36%30

ARVNArvinas Inc.

$7.42+4.65%40

SDGRSchrodinger, Inc.

$28.52+4.93%36

AUPHAurinia Pharmaceuticals Inc.

$17.11+3.32%58

Held by ETFs

SNDX is in 40 US ETFs. The largest of them, with SNDX's weight in each:

Spot a number that looks wrong? Check it in SNDX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SNDX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.